Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ONL 1204

Next Previous
X
Search
Drug Profile

ONL 1204

Alternative Names: ONL-1204

Latest Information Update: 04 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ONL Therapeutics
  • Class Eye disorder therapies; Peptides; Small molecules
  • Mechanism of Action Apoprotein inhibitors; Apoptosis inhibitors; CD95 antigen inhibitors; Fas ligand protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Retinal detachment
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Retinal detachment
  • Phase I Dry macular degeneration; Open-angle glaucoma
  • Preclinical Retinitis pigmentosa

Most Recent Events

  • 29 Oct 2024 ONL Therapeutics plans a phase II trial for Dry macular degeneration in March 2025 (Intravitreous) (NCT06659445)
  • 13 Sep 2024 Efficacy data from a phase Ib trial in Dry macular degeneration released by ONL Therapeutics
  • 13 Sep 2024 ONL Therapeutics plans a phase II trial for the treatment of Dry macular degeneration

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top